What Has Been the Progress and Growth of the Chronic Pruritus Therapeutics Market in Recent Years?
The chronic pruritus therapeutics market has seen considerable growth due to a variety of factors.
• The market size for therapeutics related to chronic pruritus has experienced robust growth over the past few years. It is anticipated to expand from $10.17 billion in 2024 to $10.94 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.6%.
This upward trajectory during the historical duration is linked to factors such as the escalating incidence of chronic pruritus, increasing need for effective therapies, growth in regulatory endorsements, a surge in product approvals, and a rise in amalgamations, collaborations, and purchases among industry participants.
What Can Be Expected from the Chronic Pruritus Therapeutics Market Size In The Coming Years?
The chronic pruritus therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of chronic pruritus therapeutics is slated to witness substantial expansion in the near future, escalating to reach $14.49 billion by 2029 at a compound annual growth rate of 7.3%.
The propelling factors for this predictable growth during the forecast period are heightened awareness, a surge in atopic dermatitis, the trend toward individualized treatments, increased occurrences of skin conditions, and larger patient demographic. The skyline of the future market is expected to be dominated by the introduction of ground-breaking medications, the creation of unique biologics and specialized therapies, advanced technology integration, utilization of sophisticated drug delivery methods, alliances forming between drug manufacturers and research institutions, and the rise of digital health platforms, including telemedicine.
What Are The Key Drivers Fueling Growth In The Chronic Pruritus Therapeutics Market?
The growth of the chronic pruritus therapeutics market is being driven by the increasing incidence of atopic dermatitis. Atopic dermatitis (AD) is a long-lasting skin disorder marked by symptoms such as redness, itching, dryness, and irritation, and it's often seen in people with a familial history of allergies, asthma, or hay fever. The rising incidence of this condition can be traced back to multiple factors, including genetic factors, changes in the environment, lifestyle choices, the hygiene hypothesis, increased exposure to allergens, and imbalances in the skin's microbiome. Chronic pruritus therapeutics help relieve the constant itchiness that comes with atopic dermatitis by acting on the inflammation pathways, lessening skin irritation, and enhancing patient comfort. For example, data from the International Eczema Council, a US-based nonprofit organization, showed that in 2022, roughly 223 million people worldwide had atopic dermatitis (as per GBD 2022), among them 43 million kids between the ages of 1-4, underscoring the high prevalence of the disease in early childhood. Hence, the increasing incidence of atopic dermatitis is fueling the expansion of the chronic pruritus therapeutics market.
How Is The Chronic Pruritus Therapeutics Market segmented?
The chronic pruritus therapeutics market covered in this report is segmented –
1) By Product Type: Corticosteroid, Antihistamine, Local Anesthetic, Counterirritant, Immunosuppressant, Calcineurin Inhibitors, Other Product Types
2) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Other Disease Types
3) By Distribution Channel: Hospital Pharmacies, Drug stores And Retail Pharmacies, Online Providers
Subsegments:
1) By Corticosteroid: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids
2) By Antihistamine: First-Generation Antihistamines, Second-Generation Antihistamines
3) By Local Anesthetic: Topical Local Anesthetics, Injectable Local Anesthetics
4) By Counterirritant: Menthol-Based Counterirritants, Camphor-Based Counterirritants
5) By Immunosuppressant: Systemic Immunosuppressants, Topical Immunosuppressants
6) By Calcineurin Inhibitors: Tacrolimus-Based Therapy, Pimecrolimus-Based Therapy
7) By Other Product Types: Biologic Therapies, Emerging Novel Therapies
Pre-Book The Chronic Pruritus Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Chronic Pruritus Therapeutics Market?
Leading corporations in the chronic pruritus therapeutics market are concentrating their efforts on creating innovative treatments such as intravenous (IV) injection, with the aim of improving treatment effectiveness and offering quicker relief to patients. Pruritus is treated using intravenous injection by delivering medication, like antihistamines or corticosteroids, straight into the bloodstream to instantly alleviate itching and decrease inflammation. For instance, in September 2023, US-based company Cara Therapeutics Inc., known for creating therapeutics, announced that its partner, Japan-based company Maruishi Pharmaceutical Co. Ltd., had received approval from Japan's Ministry of Health, Labour and Welfare for their Korsuva IV injection syringe to treat pruritus in hemodialysis patients. This endorsement was based on the positive results of their Phase 3 clinical trial performed in collaboration with Kissei Pharmaceutical Co., Ltd. The treatment demonstrated significant betterment in itching scores compared to a placebo and was well-tolerated by sufferers. As part of the terms of their deal with Maruishi, this approved triggered a $1.5 million milestone payout to Cara Therapeutics, the developer of Korsuva.
Who Are the Key Players In The Chronic Pruritus Therapeutics Market?
Major companies operating in the chronic pruritus therapeutics market are:
• Pfizer Incorporated
• AbbVie Inc.
• Sanofi S.A.
• Novartis Aktiengesellschaft
• GlaxoSmithKline plc
• Toray Industries Inc.
• CSL Behring LLC
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Ipsen S.A.. Incyte Corporation
• Cipla Limited
• H. Lundbeck A/S
• Sumitomo Pharma Co. Ltd.
• Mallinckrodt Pharmaceuticals plc
• Kissei Pharmaceutical Co. Ltd.
• Asana BioSciences LLC
• Vanda Pharmaceuticals Inc.
• Dermavant Sciences Inc.
• Galderma Laboratories L.P.
• Cara Therapeutics Inc.
• Avior Bio Inc.
• Trevi Therapeutics Inc.
What Is The Most Dominant Region In The Chronic Pruritus Therapeutics Market?
North America was the largest region in the chronic pruritus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
